Related News
Home 禄 Business 禄 Manufacturing
Firms join hands in anticancer drug deal
Source: Agencies |
June 2, 2009, Tuesday
|
Print Edition
Print Edition
DRUG developers AstraZeneca Plc and Merck & Co said yesterday that they will jointly develop a combination treatment for cancer.
The firms said they will combine efforts with Merck's MK-2206 and AstraZeneca's AZD6244, both of which are still in very early development.
They said in a statement that pre-clinical studies - the laboratory phase of development - indicate the combination has potential as an anticancer drug.
The drug candidates are currently in separate early-stage studies involving people. Under the deal, the firms will jointly evaluate the combination in a Phase I clinical trial. They will share development costs.
Decisions on further development will be based on the early-stage study.
The early stages of drug development focus mainly on whether the compound is safe and can reach its intended target.
They normally only involve a small population of patients. Results from later stages of development, involving a higher number of patients, are used to see if a treatment actually works.
The firms said they will combine efforts with Merck's MK-2206 and AstraZeneca's AZD6244, both of which are still in very early development.
They said in a statement that pre-clinical studies - the laboratory phase of development - indicate the combination has potential as an anticancer drug.
The drug candidates are currently in separate early-stage studies involving people. Under the deal, the firms will jointly evaluate the combination in a Phase I clinical trial. They will share development costs.
Decisions on further development will be based on the early-stage study.
The early stages of drug development focus mainly on whether the compound is safe and can reach its intended target.
They normally only involve a small population of patients. Results from later stages of development, involving a higher number of patients, are used to see if a treatment actually works.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
